Chapter 48: Drugs for Diabetes

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

You know, usually when we talk about a medical diagnosis, there's this expectation of precision.

Right, like a binary event.

Exactly, like engineering.

Yeah.

You break your arm, the x -ray shows that jagged white line, and the doctor just points and says, there it is, broken.

The bone is either fractured or it's intact.

The treatment path is straightforward.

Yeah, but then you step into the world of metabolic disorders,

specifically diabetes, and suddenly that x -ray machine is, well, completely useless.

Completely.

As a clinician, you're looking at a diagnostic and pharmacological landscape that is incredibly complex.

It's really a cascading failure of an entire system.

It is.

So welcome to your personal deep dive.

Consider this your one -on -one tutoring session designed to help you absolutely master Chapter 48 from Lens Pharmacotherapeutics.

Our mission today is to build you a rock -solid clinical decision -making framework for diabetes management.

Right, from the underlying pathophysiology all the way to rescuing a patient in a hyperglycemic crisis, we're getting you ready for the clinic.

And to build that framework, we have to establish the baseline of what's actually happening in your patient's body.

The underlying mechanics.

Exactly.

Fundamentally, diabetes is a disorder of carbohydrate metabolism.

But, you know, the disruption doesn't stop there.

It never does.

Right.

The disease brings alongside it disrupted protein and lipid metabolism as well.

The symptoms your patients experience mainly result from either a total deficiency of insulin or profound cellular resistance to insulin's actions.

Let's visualize this.

I like to imagine the body's glucose management system as a factory.

Oh, that's a good analogy.

So type 1 diabetes, or T1D, is a factory where the machinery, the pancreatic beta cells, is completely broken.

Due to autoimmune destruction.

Right.

The factory floor is shut down, meaning your patient has an absolute insulin deficiency.

And that mental model works beautifully when you contrast it with type 2 diabetes, which accounts for up to 95 % of all the diagnosed cases you'll see in practice.

Wow, 95%.

Yeah, the vast majority.

In the T2D factory, the machinery actually still works.

The pancreas is synthesizing insulin.

But the workers are the problem, right?

Exactly.

The receptors on the target tissues, like the liver, muscle, and adipose tissue, they're exhausted.

They're actively ignoring the foreman's instructions.

So the insulin is there, flowing through the system, but the cells just aren't listening.

Right.

And over time, the pancreas just burns out, trying to shout over that resistance, which leads to impaired insulin secretion.

The massive difference in what's going wrong.

Even if the end result for your patient is the same, which is sustained hyperglycemia.

Exactly.

And we have to mention pregnancy here.

Gestational diabetes adds a whole other layer of complexity for the clinician.

It really does.

The hormonal environment of pregnancy creates a unique glycemic challenge.

Three major factors make control difficult.

Okay, what's the first one?

First, the placenta produces hormones that actively antagonize insulin's actions.

Second, the maternal production of cortisol, which is a hormone that promotes hyperglycemia, increases threefold.

Wait, threefold?

Yes, a massive increase.

So the pregnant patient's body is actively fighting the insulin it has.

Right.

Both of those factors drastically increase the body's need for insulin.

And the third factor involves the fetal impact.

Because they share a blood supply.

Basically, yeah.

Glucose passes freely from the maternal circulation to the fetal circulation.

Okay.

Consequently, maternal hyperglycemia stimulates excessive secretion of insulin in the fetus.

Oh, wow.

And that can lead to multiple adverse effects, including macrosomia, which means a significantly larger baby.

So you know what's broken in the factory.

But before you can prescribe a treatment, you have to measure the damage and, well, track your progress.

Let's talk about the diagnostic roadmap you'll use in the clinic.

Based on the clinical guidelines in Table 48 .2, you need to memorize three specific numbers to confirm a diagnosis.

Three numbers.

Got it.

First, a fasting plasma glucose, or FPG, of 126 milligrams per deciliter or higher.

Second, a two -hour oral glucose tolerance test of 200 milligrams per deciliter or higher.

Right.

And the third.

Or a hemoglobin A1C of 6 .5 % or higher.

And for context, the warning zone of pre -diabetes is a fasting glucose between 100 and 100 and 125.

Exactly.

That's your window to intervene early.

Once you make that diagnosis, the transition in monitoring technology over the years has been fascinating.

Oh, absolutely.

Historically, you'd send your patient home with a mandate for self -monitoring of blood glucose, you know, daily finger sticks.

Which patients historically hated.

Yeah, exactly.

But now, you're much more likely to prescribe a continuous glucose monitor, or CGM, which measures interstitial glucose every five minutes.

And that continuous data stream correlates very well with plasma glucose.

It provides a dynamic picture rather than a static snapshot.

But your gold standard for long -term tracking is still the hemoglobin A1C, right?

Yes, because it provides an index of average glucose levels over the prior two to three months.

It gives you the big picture.

Picture your patient sitting on the exam table.

They see a 150 on their home monitor, but you're looking at lab results saying their A1C is 7%.

Right, there's a disconnect there.

Yeah, you have to bridge that communication gap for them.

Because a percentage means nothing to someone tracking daily milligrams per deciliter.

So you translate that using the estimated average glucose, or EAG.

How does that math work?

Well, according to Table 48 .4, an A1C of 7 % translates to an EAG of 154 milligrams per deciliter.

An A1C of 8 % is an average of 183.

Okay, that makes it much more tangible for the patient.

Exactly.

Your general goal for non -pregnant adults is to keep that A1C below 7%, but, and this is key, you must individualize this based on your patient's specific risks, comorbidities, and life expectancy.

So you have your target of 7%.

How do you actually get your patient there without, you know, overwhelming them?

You use the 20 -23 ADA clinical guidelines.

They map out a logical, stepped approach to management.

Let's walk through that algorithm for your type 2 diabetes patients.

Okay, step one begins immediately at diagnosis.

You initiate lifestyle changes, and you simultaneously start the drug metformin.

Wait, simultaneously?

You don't wait to see if diet and exercise work alone?

No, you do not wait.

The guidelines dictate starting the medication right away, along with the lifestyle changes.

That makes sense.

You hit it from both behavioral and pharmacological angles immediately,

but let's say they come back for a follow -up, and that A1C is still hovering around 8%.

You have to escalate.

Then you move to step two.

You continue the lifestyle changes in metformin, and you add a second high -efficacy drug.

On what?

This might be a glucagon -like peptide -1 receptor agonist, a GLP -1RA, or a basal insulin.

Okay, and if they still miss the target?

Step three is progressing to a three -drug combination.

And this is where your clinical judgment really comes into play, right?

You don't just pick a third drug at random.

Exactly.

You have to look at the patient's whole profile.

If your patient has a history of cardiovascular disease or high renal disease risk, the guidelines strongly suggest adding an SGLT -2 inhibitor.

You're tailoring the pharmacology to their specific organ risks.

You must also consider social determinants of health, like cost, insurance coverage, and patient preference.

Which are huge factors in real -world compliance.

Absolutely.

However, there are critical exceptions to this stepwise staircase.

Oh, right.

When do you skip steps?

If a patient presents with an A1C of 9 % or greater at the time of diagnosis, you skip step one entirely.

You consider starting immediately at step two with dual therapy.

Wow.

And if their A1C is 10 % or greater, or their fasting glucose is over 300...

Then the metabolic house is fully on fire.

At that point, you bypass the oral step -up entirely and start combination injectable therapy immediately.

Which leads us to the most powerful tool you have in your clinical arsenal, exogenous insulin.

Understanding insulin physiology is non -negotiable.

Connecting this back to the pathophysiology, you need to view insulin as a highly anabolic hormone.

Anabolic meaning it builds things up.

Right.

It builds and stores.

It promotes the cellular uptake of glucose, amino acids, and potassium, and it drives the synthesis of glycogen, proteins, and triglycerides.

And when you have an absolute deficiency, like in your type 1 patients, the body flips into a destructive, catabolic state.

Without insulin to build, the body begins to break down its own stores.

It converts glycogen back into glucose.

It degrades proteins into amino acids.

And it converts fats into free fatty acids to fuel gluconeogenesis.

It's just tearing itself apart for energy.

Reversing that catabolic state requires precise administration of insulin preparations.

Let's talk about the timeline chart in the text table 48 .6.

It categorizes these by time course.

Right.

And you need to know the prototypes.

First, the short duration, rapid acting insulins, like Lispro.

OK, Lispro.

Because of its incredibly fast onset, you must instruct your patients to administer it right before meals to cover the postprandial spike in glucose.

Then you have your short duration, short acting regular insulin, but we need to pause here for a massive safety alert regarding the U500 formulation of regular insulin.

Yes, this is a critical safety issue.

Imagine you're working in the clinic or the hospital.

Most regular insulin is U100, meaning 100 units per milliliter.

Right.

But U500 is five times more concentrated.

Five times?

It is reserved exclusively for patients with extreme insulin resistance who require massive daily doses.

So if you or your patient accidentally uses a standard U100 syringe to draw up a U500 dose, you will administer a life -threatening five -fold overdose.

Wow!

The text highlights that for a reason.

It is a terrifying medication error.

It really is.

Moving down the timeline, you have intermediate acting NPH insulin.

Now if you look at a vial of NPH, it's cloudy.

Right, it's visibly cloudy.

Why?

Because the regular insulin is conjugated with a large protein called protamine.

This delays absorption, giving it a slower onset and a longer duration.

Finally, we have the long and ultra -long acting Bezel insulins, with Glargine serving as our prototype.

How does Glargine work?

When a patient injects Glargine, it forms microprecipitates in the subcutaneous tissue.

These slowly dissolve, releasing small amounts of insulin over 24 hours.

So there's no big spike in the blood.

Exactly.

There is no discernible peak.

It just provides steady background coverage.

So your patient might use an intensive Bezel bolus strategy, like a shot of long -acting Glargine once a day and a rapid -acting Lispro shot at every single meal.

Right, that's very common.

But let's say they're on a regimen where they need to mix insulins in a single syringe to reduce the number of injections.

You have to teach them the strict mixing rule.

Of the longer -acting insulins, only NPH is appropriate for mixing with short -acting insulins.

OK, so NPH only.

What's the sequence?

When drawing them into one syringe, the patient must always draw up the short -acting clear insulin first, clear before cloudy.

Clear before cloudy.

Why is that sequence so important?

Because it ensures that the protamine from the cloudy NPH vial doesn't accidentally contaminate the vial in rapid or short -acting clear insulin.

Oh, because that would alter its pharmacokinetics.

Exactly.

It would slow down your fast -acting insulin, which defeats the purpose.

Managing all this insulin means managing adverse effects.

The primary risk you constantly monitor for is hypoglycemia.

You also watch for hypoglycemia, because insulin drives potassium into the cells along with the glucose.

Right, and lipohypertrophy, which is an accumulation of subcutaneous fat.

You must educate your patients to rotate their injection sites.

Speaking of hypoglycemia, there is a profound drug interaction you must recognize regarding beta blockers.

This is a vital clinical pearl.

When a patient's blood sugar drops precipitously, the sympathetic nervous system activates.

Right, that sympathetic surge causes rapid heartbeat, palpitations, and nervousness.

It's the physical warning alarms alerting the patient to, you know, consume carbohydrates.

Yes.

But beta blockers suppress that tachycardia.

Wait, beta blockers don't just lower blood pressure.

They suppress that specific warning sign.

So if your patient is on a beta blocker for hypertension, you've essentially silenced their body's early warning system for a hypoglycemic crash.

Oh, wow.

That's incredibly dangerous.

It creates a state of hypoglycemia unawareness.

And furthermore, the body's natural defense against falling blood sugar is to break down stored glycogen in the liver.

Beta blockers actively impair that process of glycogenolysis, so they mask the symptoms and simultaneously prevent the body from naturally counter -regulating the low blood sugar.

That is a clinical pearl you will use constantly.

Definitely.

Now, while insulin replaces the missing machinery, the oral antidiabetic drugs for your type 2 patients work by altering how the factory operates.

Let's start with the first -line champion we mentioned in the ADA guidelines.

The big oneides, specifically metformin.

Right, metformin.

Metformin is unique because of what it does not do.

Its primary mechanism of action is decreasing glucose production by the liver and sensitizing tissue receptors to insulin.

Okay.

Crucially, it does not stimulate the pancreas to release more insulin.

So if it's just modulating the liver and sensitizing the tissues,

essentially upgrading the worker's headsets so they hear the insulin form and better,

the risk of hypoglycemia is practically zero.

Exactly.

It doesn't actively drive blood sugar down like a hammer.

But it does carry a severe black box warning for lactic acidosis, right?

Yes.

Because metformin is not metabolized, it is excreted entirely unchanged by the kidneys.

Any renal impairment means the drug will accumulate to toxic levels.

So renal impairment is a strict contraindication.

Strict.

This is exactly why you have to hold metformin before a patient receives iodinated radio contrast media for a CT scan.

Right, because the contrast dye can cause acute renal failure.

And if that happens while metformin is in their system, the drug gets trapped, accumulates, and triggers lactic acidosis.

You also need to monitor them for B12 deficiency and educate them about common GI side effects like diarrhea, which generally subside over time.

Contrast metformin's mechanism with our secretagogs, the sulfonylureas like liposide and the glinides like rapaglinide.

These drugs bind to ATP -sensitive potassium channels on the pancreatic beta cells.

They actively force the pancreas to secrete more insulin.

If we go back to our factory, these drugs put a megaphone on the foreman to shout at the exhausted workers.

That's a good way to look at it.

But because they actively squeeze the pancreas to release insulin regardless of the current blood sugar, they absolutely do cause hypoglycemia.

They do.

And because insulin is an anabolic fat -storing hormone, they also cause weight gain.

You must also warn patients about a desulfuram -like reaction, you know, flushing palpitations and nausea if they consume alcohol while on a sulfonylurea.

And for the glinides, patient education regarding timing is paramount.

Right.

A patient taking rapaglinide must eat within 30 minutes of taking the pill because it acts so quickly.

Yes.

If they delay the meal, they risk severe hypoglycemia.

What if your patient's beta cells are completely exhausted or they have specific comorbidities?

You'll likely turn to the sensitizers and modulators.

Sure.

Let's look at the thiazolid and dianas.

With pioglutazone as our prototype.

Right.

Pioglutazone decreases insulin resistance by activating specific receptors in the cell nucleus called PPR gamma.

By altering gene transcription, it increases cellular responsiveness to insulin.

That sounds great, but there's a catch, right?

There is.

It carries a significant black box warning for heart failure secondary to fluid retention.

And for you sitting in the clinic, the guidelines are clear.

Pioglutazone is strictly contraindicated in severe heart failure, specifically NYHA class 3 and 4.

Right.

We're talking about patients who are symptomatic just walking across the room or even at rest.

Adding fluid retention to that compromised heart is extremely dangerous.

You also have to monitor for unique risks like bladder cancer and bone fractures in women.

Another fascinating class is the alpha -glucosidase inhibitors, like a CARBOS.

How do those work?

These agents work locally in the gut.

They inhibit the enzyme that breaks down complex carbohydrates, literally delaying carb digestion to blunt the post -meal glucose spike.

But the trade -off is intense.

Those unobsorbed carbohydrates sit in the colon and ferment, causing significant flatulence and cramping.

It can be very uncomfortable, and there is a massive safety alert you need to remember here.

Oh, regarding rescue protocols.

Yes.

If your patient becomes hypoglycemic on a CARBOS, perhaps because they are also on a sulfonylurea,

you cannot rescue them with table sugar, which is sucrose.

Because the A -CARBOS blocks the breakdown of sucrose.

Exactly.

The sugar will just remain undigested in their gut while their blood sugar continues to crash.

Wow.

You absolutely must rescue them with pure, simple glucose.

That's such an important clinical detail.

Next up, the DPP -4 inhibitors, like cytoclyptin.

These work by inhibiting the enzyme that naturally breaks down our body's incretin hormones.

By keeping those incretins active longer, they increase insulin release and reduce glucagon.

They are generally safe, but keep pancreatitis on your differential diagnosis if a patient reports severe abdominal pain.

Good to know.

Then we have the SGLP -2 inhibitors, such as empagliflucin.

I appreciate the metaphor you used earlier for the kidney bouncers.

It really is the best way to picture it.

They stand at the renal tubules, acting like bouncers at the exit doors of the factory, actively blocking the reabsorption of sugar and tossing the excess glucose out into the urine.

And because they are dumping massive amounts of sugar into the urinary tract, the adverse effects are highly predictable.

Right.

The urinary exit doors are basically bathed in glucose.

Exactly.

Which creates an ideal environment for bacteria and yeast.

This leads to high risks for urinary tract infections and female genital mycotic infections.

And what about fluid loss?

Well, because water follows sugar out of the body through osmotic diuresis, you must monitor your patients for volume depletion and orthostatic hypotension.

Now, if the oral medications aren't reaching the A1C targets, you're going to bridge the gap with non -insulin injectables.

Right.

These medications leverage powerful gut hormones.

First, the GLP -1 receptor agonists, which are the incretin mimetics like exinotide and liraglutide.

These agents are structurally related to the native GLP -1 hormone, right?

Yes, but they are resistant to enzymatic degradation.

They perform four critical actions.

Let's list them out.

They slow gastric emptying, they stimulate glucose -dependent insulin release, they suppress postprandial glucagon, and they act on the brain to drastically reduce appetite.

Which leads to profound weight loss.

It does, but you have to discuss the black box warning with your patient.

Right, regarding the thyroid.

Yes.

Animal studies showed a risk for thyroid C -cell tumors, so you avoid these in patients with a family history of medullary thyroid carcinoma.

You also monitor for pancreatitis.

And speaking of weight loss, the newest class GIP and GLP -1 receptor agonists, with terzepotide, is the pioneer.

Terzepotide utilizes a dual mechanism, mimicking both GIP and GLP -1.

The resulting appetite suppression and weight loss observed in clinical trials are staggeringly high.

It's really reshaping how we approach obesity alongside diabetes.

It's revolutionary.

Finally, in the injectables, we have the amylen mimetics, specifically, pramalentide.

Amylen is a hormone co -released with insulin from the pancreas, right?

Pramalentide is a synthetic analog used as a supplement to mealtime insulin in both T1D and T2D.

But there's a serious black box warning for pramalentide that requires immediate clinical attention.

Yes.

When you combine pramalentide with mealtime insulin, the risk for severe hypoglycemia is exceptionally high.

So what's the intervention?

You must proactively reduce their initial mealtime insulin doses.

Oh, that makes sense.

Furthermore, because it slows gastric emptying, you must educate patients to take their oral drugs either one hour before or two hours after injecting pramalentide.

To prevent erratic drug absorption.

Exactly.

So you've optimized their pharmacology, you've taught them the timings, but sometimes, despite our best efforts, the system fails.

It happens.

We conclude with the acute complications you will face in emergency situations.

Diabetic ketoacidosis, or DKA,

and the hyperosmolar hyperglycemic state,

or HHS.

Let us examine DKA first.

It primarily occurs in type 1 diabetes and presents with a rapid onset.

The pathophysiology is severe.

Without any insulin to suppress it, there are policies the breakdown of fat runs unchecked.

Right.

The liver is flooded with free fatty acids, which it rapidly converts into ketoacids.

That flood of acids lowers the blood pH, giving the patient that classic fruity, juicy fruit breath,

and causes extreme osmotic diuresis, leading to profound dehydration.

Your treatment protocol requires immediate intravenous fluids to fix the dehydration, electrolyte replacement, and IV insulin.

But critically, you must reduce the glucose, slowly dropping it, by about 50 mg per deciliter per hour.

Yes.

If you drop it too fast, water rushes into the brain cells, causing fatal cerebral edema.

Wow.

So you have to be incredibly precise.

Now, contrast that dramatic presentation with HHS, which primarily occurs in type 2 diabetes.

HHS has a gradual onset over weeks or months.

The patient's blood glucose climbs much higher than in DKA, often exceeding 600 mg per deciliter.

They experience massive osmotic diuresis, leaving their blood profoundly thick and hyperosmolar.

Yes.

But wait, their blood sugar is way higher, yet there is no ketoacidosis in HHS.

That has to be because it's type 2, right?

The pancreas is still sputtering out just enough endogenous insulin to keep the body from completely cannibalizing its fat stores, even if it can't handle the massive glucose load.

That deduction is clinically perfect.

The residual insulin prevents lipolysis, so no ketones are formed.

Okay, so how does treatment differ?

The treatment mirrors DKA fluids, electrolytes, and insulin, but without the need to correct profound acidosis.

And lastly, what if the crisis is severe hypoglycemia?

You find a patient unconscious from an insulin overdose.

They can't swallow an oral carbohydrate, so intravenous glucose is your immediate rescue.

But if you don't have IV access… You administer glucagon.

Glucagon forces the liver to rapidly break down its stored glycogen into free glucose, spiking the blood sugar enough to restore consciousness.

It's the ultimate pharmacological countermeasure.

When the system swings too far into the hypoglycemic zone.

It truly is.

Let's take a breath and look at the massive clinical framework you've just built.

We started in the factory of the pancreas, navigating the broken machinery of Type I and the exhausted workers of Type II.

We covered a lot of ground.

We walked through the ADA step guidelines, the critical U500 safety alerts, the intricate mechanisms of oral and injectable drugs, all the way to rescuing a patient from the brink of DKA.

You are ready to apply Chapter 48.

It is a profound amount of pharmacology, but it all connects back to a singular goal, restoring metabolic balance.

I'd like to leave you with a final thought to consider as you step into practice.

We explored how GLP -1 and GIP receptor agonists not only manage blood glucose, but exert a massive impact on satiety and weight loss.

Yeah, the terzipatide trials were wild.

So as these drugs become increasingly prevalent, how will this pharmacological revolution blur the lines between treating a metabolic disease and fundamentally altering society's biological approach to human appetite?

Wow.

That is a question you're going to be answering on the front lines of healthcare very soon.

The factory isn't just getting new workers.

The whole management philosophy of metabolic medicine is changing.

It certainly is.

Thank you for taking this deep dive with us.

Your dedication to mastering this material is going to make you an incredible, life -saving clinician.

From the Last Minute Lecture team, thank you for listening and we'll see you on the next Deep Dive.